ARAVIVE INC. news, videos and press releases
For more news please use our advanced search feature.
ARAVIVE INC. - More news...
ARAVIVE INC. - More news...
- Aravive, Inc. to Delist from The Nasdaq Stock Market
- Aravive Announces Top-Line Results from Phase 3 AXLerate-OC Study of Batiraxcept in Platinum-Resistant Ovarian Cancer
- Aravive to Present Updated Clinical Data from Batiraxcept Trials in Renal and Pancreatic Cancer at ESMO Congress 2023
- Aravive to Participate in William Blair’s Innovator Series: Transitioning Biotech Breakthroughs to Commercial Success Being Held July 18, 2023
- Aravive Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)
- Aravive To Participate in the Jefferies Global Healthcare Conference
- Aravive to Present Promising Updated Data from Phase 2 Trial of Batiraxcept in Combination with Cabozantinib in Clear Cell Renal Cell Carcinoma at ASCO 2023
- Aravive Announces Phase 3 Trial Design for Batiraxcept in Clear Cell Renal Cell Carcinoma
- Aravive Reports First Quarter 2023 Financial Results and Provides Corporate Updates
- Aravive to Host Virtual KOL Event on its Late-Stage Oncology Asset Batiraxcept
- Aravive Announces Poster Presentation on Batiraxcept at 2023 ASCO Annual Meeting
- Aravive Appoints Carolina Petrini as Chief Commercial Officer
- Aravive Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Updates
- Aravive Announces FDA Orphan Drug Designation Granted to Batiraxcept for the Treatment of Pancreatic Cancer
- Aravive to Present Positive Updated Data from Phase 1b Trial of Batiraxcept in Combination with Cabozantinib for Treatment of Clear Cell Renal Cell Carcinoma at the 2023 ASCO Genitourinary (GU) Cancers Symposium
- Aravive Announces Complete Enrollment in the Global Registrational Phase 3 AXLerate-OC Trial for Platinum-Resistant Ovarian Cancer
- Aravive Announces Fast Track Designation of Batiraxcept for Treatment of ccRCC
- Aravive To Participate in Piper’s 34th Annual Healthcare Conference
- Aravive Regains Compliance with Nasdaq Minimum Bid Price Requirement
- Aravive Reports Third Quarter 2022 Financial Results and Provides Corporate Updates
- Aravive Announces Approximately $41.5 Million Private Placement Financing
- Aravive Receives Third Development Milestone from 3D Medicines
- Aravive to Participate in the Cantor Fitzgerald Oncology & HemOnc Conference
- Aravive to Participate in H.C. Wainwright 24th Annual Global Investment Conference
- Aravive Reports Second Quarter 2022 Financial Results and Provides Corporate Updates
- Aravive Appoints Dr. Robert B. Geller as Chief Medical Officer
- Aravive Appoints Rudy Howard as Chief Financial Officer
- Aravive Presents Updated Clinical Data at ASCO Showing Continued Best-in-Class Potential of Batiraxcept in Advanced or Metastatic clear cell Renal Cell Carcinoma (ccRCC)
- Aravive to Participate in H.C. Wainwright Global Investment Conference
- Aravive Reports First Quarter 2022 Financial Results and Provides Corporate Updates
